Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
Мақола

68P The effectiveness of treatment of ascites due to recurrence of platinum-refractory ovarian cancer using metronomic chemotherapy

S. ShaxanovaMedical Oncology Department, Republican Specialized Scientific Center of Oncology and Radiology Samarkand Branch, Samarkand, Uzbekistan
ESMO Openjournal2024en
ABI

Аннотация

The growth rate of this indicator compared to 2020 was 16.4%, and among the female population: breast cancer (24.0), cervical cancer (10.6), and ovarian cancer (5.7 per 100,000 population). The incidence of ovarian cancer (RY) throughout the world and in Uzbekistan tends to constantly increase. In Uzbekistan, the incidence was 5.7 per 100,000 population in 2021; in 2015, this figure was 4.7. The object of the study was 116 female patients with a verified diagnosis of ovarian cancer complicated by ascites (OCA) who were treated at the Russian National Medical Research Center for Medical and Radiological Research as well as at the Samarkand branch from 2017 to 2023. Patients were randomized as follows: Group 1 received standard palliative therapy: gemcitabine 1000 mg/m2 on days 1, 8, 15, and bevacizumab at a dose of 7.5–15 mg/kg once every 3 weeks (n = 42); Group 2 patients receiving metronomic chemotherapy:cyclophosphamide 50 mg/day orally daily without a break (n = 33); and Group 3 patients receiving metronomic chemotherapy: cyclophosphamide 50 mg/day. orally daily without interruption, and pazopanib 400 mg days 1–28 (n = 41). Please see the table below.Table: 68PStudy GroupsGroup 1, n=42Group 2, n=33Group 3, n=41absM (%)mabsM (%)mabsM (%)mFull effect00.000.0000.000.0000.000.00Partial effect1433.337.271442.428.601843.907.75Stabilization1023.815.571030.308.001435.15*4.41Progression1842.867.64927.27*7.75921.95*6.4 Open table in a new tab Was developed a new method of metronomic maintenance chemotherapy, which is the use of cyclophosphamide and pazopanib in low doses in patients with ascites caused by platinum-resistant recurrent ovarian cancer after completion of second-line chemotherapy. This method helps to achieve disease control in 65.7% of patients and increase the median time to progression from 7.4 to 9.1 months. (plog-rank <0.0001), median overall survival observed from 15.0 to 22.7 months. (plog-rank = 0.0005).

Ҳали таржима қилинмаган

Мавзулар

Идентификаторлар

Иқтибослар ва манбалар

0 та иқтибос0 та фойдаланилган манба